Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eleven Bio Inc (EBIO)

Eleven Bio Inc (EBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eleven Bio Inc 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 USA

www.elevenbio.com P: 617-871-9911

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 157,229
Shares Outstanding, K 47,790
% of Insider Shareholders 28.70%
% of Institutional Shareholders 13.96%

Financials:

Annual Sales, $ 430 K
Annual Net Income, $ -29,030 K

Growth:

1-Year Return 100.61%
3-Year Return 9.67%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 158.14%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/13/18
Earnings Per Share ttm -0.89
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 56.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

EBIO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -132.45%
Return-on-Assets % -33.33%
Profit Margin % -6,751.16%
Debt/Equity 0.00
Price/Sales 297.98
Price/Cash Flow N/A
Price/Book 6.58
Book Value/Share 0.00
Interest Coverage 0.00
60-Month Beta 2.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.